Financial Advocates Investment Management Has $5.94 Million Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Financial Advocates Investment Management cut its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 1.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 14,876 shares of the biotechnology company’s stock after selling 272 shares during the quarter. Financial Advocates Investment Management’s holdings in Axon Enterprise were worth $5,944,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Blue Trust Inc. raised its position in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 79 shares during the period. Quent Capital LLC raised its position in shares of Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 75 shares during the period. Asset Dedication LLC acquired a new position in shares of Axon Enterprise during the second quarter worth approximately $47,000. Friedenthal Financial acquired a new position in shares of Axon Enterprise during the third quarter worth approximately $51,000. Finally, Cullen Frost Bankers Inc. acquired a new position in shares of Axon Enterprise during the second quarter worth approximately $59,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the sale, the director now owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the sale, the director now owns 26,259 shares of the company’s stock, valued at $11,500,916.82. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the completion of the sale, the director now directly owns 4,892 shares of the company’s stock, valued at approximately $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 371,172 shares of company stock valued at $137,000,162. Insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Robert W. Baird upped their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Bank of America assumed coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price objective for the company. Northland Securities increased their price target on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Craig Hallum increased their price target on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group started coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 target price for the company. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $382.85.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $439.00 on Thursday. The company’s fifty day moving average price is $400.22 and its 200-day moving average price is $339.14. The firm has a market capitalization of $33.13 billion, a price-to-earnings ratio of 128.36, a PEG ratio of 11.91 and a beta of 0.94. Axon Enterprise, Inc. has a one year low of $199.50 and a one year high of $455.17. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. During the same quarter in the prior year, the firm earned $0.80 EPS. The business’s revenue for the quarter was up 34.5% compared to the same quarter last year. On average, equities research analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.